´Ù¹ß°ñ¼öÁ¾¿¬±¸È¸ Update on MM (Multiple myeloma) 2023 : 2023-02-04±³À°ÀÏÀÚ : 2023-02-04
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI hall
±³À°ÁÖÁ¦ :
Update on MM (Multiple myeloma) 2023 ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´Ù¹ß°ñ¼öÁ¾¿¬±¸È¸
´ã´çÀÚ : ¼È¿Áø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ :
kmmwp_office@naver.com ±³À°Á¾·ù : ³»°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 130¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 5 ½Ã°£ 5ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í »çÀüµî·ÏÀÌ Á¶±â ¸¶°¨ µÉ ¼ö ÀÖ½À´Ï´Ù.
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-04 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI hall 09:30~09:55 Genomics and epigenomics of MM ±è¹Ì¿µ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 02-04 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI hall 09:55~10:20 Immunologic studies of MM Á¶Çö¼ö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 02-04 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI hall 10:20~10:45 MGUS and smoldering MM ¼Û°¡¿µ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 02-04 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI hall 10:55~11:25 Treating myeloma patients in real world practice Ajai Chari(Icahn School of Medicine at Mount Sinai/USA)
±³À°½Ã°£ 02-04 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI hall 11:30~11:55 Imaging approaches for MM Á¶ÈñÁ¤(°æºÏÀÇ´ë)
±³À°½Ã°£ 02-04 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI hall 11:55~12:20 MRD assessment ½Å»õ¾Ï(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 02-04 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI hall 13:10~13:35 Frontline therapy for transplant-eligible patients ÀÌÁØÈ£(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 02-04 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI hall 13:35~14:00 Frontline therapy for transplant-ineligible patients Á¤Á¾Çå(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 02-04 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI hall 14:10~14:35 Treatment for RRMM other than immunotherapeutics ¾ç½Â¾Æ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 02-04 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI hall 14:35~15:00 Immune therapy for RRMM (I) À±»óÀº(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 02-04 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI hall 15:00~15:25 Immune therapy for RRMM (II) Á¶Çü¿ì(¿ï»êÀÇ´ë)
±³À°½Ã°£ 02-04 ¼¼Á¾´ëÇб³ ´ë¾ç AI ¼¾ÅÍ 12Ãþ AI hall 15:25~15:50 Rare diseases including Amyloidosis, POEMS and WM ÀÌÁöÀ±(¼¿ïÀÇ´ë)